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Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) consists of a spectrum of autoimmune diseases of the periph-
eral nerves, causing weakness and sensory symptoms. Diagnosis often is challenging, because of the heterogeneous presentation
and both mis- and underdiagnosis are common. Nerve conduction study (NCS) abnormalities suggestive of demyelination are man-
datory to fulfil the diagnostic criteria. On the one hand, performance and interpretation of NCS can be difficult and none of these
demyelinating findings are specific for CIDP. On the other hand, not all patients will be detected despite the relatively high sensitiv-
ity of NCS abnormalities. The electrodiagnostic criteria can be supplemented with additional diagnostic tests such as CSF examin-
ation, MRI, nerve biopsy, and somatosensory evoked potentials. However, the evidence for each of these additional diagnostic tests
is limited. Studies are often small without the use of a clinically relevant control group. None of the findings are specific for CIDP,
meaning that the results of the diagnostic tests should be carefully interpreted. In this update we will discuss the pitfalls in diagnos-
ing CIDP and the value of newly introduced diagnostic tests such as nerve ultrasound and testing for autoantibodies, which are not
yet part of the guidelines.
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Introduction
Chronic inflammatory demyelinating polyradiculoneuropa-
thies (CIDPs) consists of a spectrum of immune-mediated
neuropathies, causing weakness and sensory symptoms in a
progressive, relapsing-remitting or monophasic fashion (Van
den Bergh et al., 2010). Early diagnosis is important, as in-
duction of treatment can prevent axonal damage and
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permanent disability (Bouchard et al., 1999; Eftimov et al.,
2013; Mehndiratta et al., 2015; Hughes et al., 2017).
Diagnosis is often challenging, because of the heterogeneous
presentation. Clinical presentation and nerve conduction
studies (NCS) play a major role in diagnosing CIDP, supple-
mented with diagnostic tests such as CSF examination, MRI,
nerve biopsy and somatosensory evoked potentials (SSEP)
(Van den Bergh et al., 2010). Recently, nerve ultrasound
and testing for autoantibodies were introduced (Goedee
et al., 2017b; Vural et al., 2018). Despite diagnostic guide-
lines, in clinical practice both mis- and underdiagnosis are
common. Misdiagnosis is a major problem, leading to the
inappropriate use of expensive and potentially harmful treat-
ment; underdiagnosis means that patients may not get effect-
ive treatment (Boukhris et al., 2004; Ayrignac et al., 2013;
Allen and Lewis, 2015; Lucke et al., 2019a). In this update
we will discuss the frequent pitfalls in diagnosing CIDP and
the value of newly introduced diagnostic tests such as nerve
ultrasound and testing for autoantibodies.
Clinical signs and symptoms
Typical CIDP is defined as proximal and distal weakness
and sensory dysfunction of all extremities, with absent or
reduced tendon reflexes in all four limbs, with a progressive,
relapsing-remitting or monophasic course, typically progress-
ing over months. Atypical CIDP may be divided, based on
clinical presentation, in the asymmetric, focal, distal, pure
motor and pure sensory variants (Van den Bergh et al.,
2010). Misdiagnosis is common and is reported in up to
50% of patients referred with a CIDP diagnosis, mainly in
patients with an atypical presentation (Allen and Lewis,
2015). In patients with a typical presentation of proximal
and distal weakness, diagnosing CIDP is often straightfor-
ward. It was even suggested to base diagnosis on a typical
presentation without further investigations (Koski et al.,
2009). However, none of the typical findings are specific for
CIDP.
Diagnostic criteria sets
Consensus on the diagnostic criteria for CIDP has proven
difficult, which led to many different sets throughout the
years. One North American study (Breiner and Brannagan,
2014) compared 15 diagnostic criteria sets, including the
revised European Federation of Neurological Societies/
Peripheral Nerve Society (PNS/PNS) criteria (Van den Bergh
et al., 2010), the van den Bergh and Piéret criteria (2004),
the American Academy of Neurology (AAN) criteria
(American Academy of Neurology, 1991) and the Koski cri-
teria (Koski et al., 2009) in 57 CIDP patients and 37
patients with diabetic neuropathy and 39 patients with
amyotrophic lateral sclerosis as control subjects (Table 1).
The EFNS/PNS criteria had the highest sensitivities, with
good specificities. Another European study (Rajabally et al.,
2009) investigated the specific electrodiagnostic criteria,
including the 2006 EFNS/PNS criteria (Hughes et al., 2006),
the van den Bergh and Piéret criteria (2004), the AAN criteria
(American Academy of Neurology, 1991) and the Koski crite-
ria (Koski et al., 2009) in 151 CIDP patients and 162 patients
with axonal neuropathies as control subjects. The EFNS/PNS
electrodiagnostic criteria had the highest sensitivity of 81%
for definite or probable CIDP, with specificities ranging from
79% to 96%, depending on the extent of the NCS. The spe-
cificity of the criteria sets are likely overestimated, as all stud-
ies used control patients with clear clinical phenotypes of
axonal neuropathies or motor neuron diseases instead of the
ideal control population with initially suspected CIDP with al-
ternative diagnosis. As the EFNS/PNS 2010 criteria seem the
most accurate and widely used set of criteria, this review will
further mainly focus on this set (Rajabally et al., 2014). All
diagnostic tests have their pitfalls and should be interpreted in
the clinical context, including considering alternative causes
of a demyelinating neuropathy (Table 2).
Diagnostic tests
Nerve conduction studies
The diagnosis of CIDP relies heavily on identification of
demyelinating features on motor NCS. The electrophysio-
logical demyelinating features are not equivalent to classical
demyelination as found in nerve biopsy, but rather are
markers for functional disruption or slowing of the saltatory
conduction of the myelinated axons. Based on the amount
and certainty of demyelinating features, this will lead to a
definite, probable or possible electrodiagnosis according to
the EFNS/PNS 2010 criteria (Van den Bergh et al., 2010). A
definite electrodiagnostic diagnosis requires at least two
demyelinating features in two different nerves. A probable
diagnosis requires two probable blocks or a probable block
and one other demyelinating feature in a different nerve,
while a possible diagnosis requires one demyelinating feature
in one nerve. Recent studies highlighted the importance of
Table 1 Sensitivities and specificities of different
diagnostic criteria sets
Criteria Sensitivity Specificity
EFNS/PNS, 2010
Definite 73% (59.7–84.2%) 88% (78.7–94.4%)
Probable 77% (63.6–87.0%) 84% (74.0–91.6%)
Possible 91% (80.4–97.0%) 65% (54.0–76.3%)
Van den Bergh and Piéret
Definite 63% (48.5–75.1%) 86% (77.1–93.5%)
Probable 66% (52.2–78.2%) 78% (68.1–87.5%)
AAN
Definite 4% (0.4–12.3%) 100% (95.3–100%)
Probable 13% (5.2–24.1%) 100% (95.3–100%)
Possible 25% (14.4–38.4%) 100% (95.3–100%)
Koski 50% (36.3–63.7%) 84% (74.0–91.6%)
AAN = American Academy of Neurology; EFNS/PNS = European Federation of
Neurological Societies/Peripheral Nerve Society. Adapted from Breiner and Brannagan
(2014).
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correct interpretation of NCS and electrodiagnostic criteria,
as this often led to misdiagnosis (Allen and Lewis, 2015;
Allen et al., 2018). A pitfall is that the electrophysiological
criteria are sensitive to diagnose a demyelinating neuropathy,
but they are also fulfilled in other diseases (Table 2).
Another frequent pitfall is severe axonal loss that can have
a profound influence on nerve conduction velocity if the
largest, fastest conducting axons are involved. For this rea-
son, several criteria have additional fulfilments for the com-
pound muscle action potential (CMAP) amplitude (Van den
Bergh et al., 2010). In general, demyelinating features should
be identified with caution in measurements with CMAP
amplitudes 51 mV, with particular focus on the clinical
context (Van Asseldonk et al., 2005). Recordings of more
proximal muscles, such as the flexor carpi radial muscle to
test the median nerve, can sometimes be of added value in
case of profound distal axonal loss.
Demyelinating features in segments prone to compression or
entrapment should not be considered as supportive for CIDP.
The most important reason is that compression or entrapment
itself can give demyelinating features. More severe demyelin-
ation was not observed at entrapment sites as compared with
that observed at other nerve segments in CIDP (Padua et al.,
2004; Rajabally and Narasimhan, 2011b).
Table 2 Diagnostic pitfalls
Diagnostic test Pitfall
Nerve conduction studies Misdiagnosis Other diseases that can meet electrodiagnostic criteria
MMN
Hereditary neuropathies with demyelinating features - CMT (demyelinating and intermediate
types)
HNLPP
IgM monoclonal gammopathy associated with anti-MAG antibodies
POEMS syndrome
Amyloidosis
Vasculitic neuropathy
Lumbosacral radiculoplexus neuropathy
Neurolymphomatosis
Misinterpretation
Increased distal latencies and slowed velocities due to severe axonal loss (low CMAP ampli-
tudes), especially for the fibular nerve
Demyelinating signs over segments prone to compression [median nerve (carpal tunnel), ulnar
nerve (elbow), fibular nerve (fibular head)]
interpreting CMAP reduction (abductor digiti minimi muscle) in forearm as a conduction block,
without excluding Martin-Gruber anastomosis
Uncertainties in determination of motor conduction block in segment axilla to Erb’s point
Absence of F-waves
Distal CMAP duration prolongation with improper cut-off values
Non-stringent interpretation of proximal CMAP amplitude reductions and temporal dispersion
in the legs, especially for the tibial nerve
Underdiagnosi Testing too few (proximal arm) nerve segments
Proximal leg nerves, including lumbosacral plexus, and partly brachial plexus are not accessible
Criteria mainly based on motor nerves
Lumbar puncture Misdiagnosis Elevated CSF protein also found in diabetes mellitus and CMT
CSF protein can increase with age
Underdiagnosis Normal CSF protein in atypical CIDP variants
Imaging Misdiagnosis Enlarged nerves also found in diseases such as vasculitis, diabetes mellitus, amyotrophic neural-
gia, demyelinating and intermediate CMT
Cut-off values for enlargement need critical attention
High inter- and intra-observer variability of qualitative MRI assessment
Underdiagnosis Sensitivity of MRI is unknown
High inter- and intra-observer variability of qualitative MRI assessment
Evoked potentials Misdiagnosis Prolonged SSEP not specific for CIDP
Underdiagnosis Sensitivity of SSEPs is unknown
Nerve biopsy Misdiagnosis Biopsy findings do not differentiate between CIDP and differential diagnoses such as axonal neu-
ropathies or vasculitis
Underdiagnosis Demyelination is often not seen in biopsy
Autoantibodies Misdiagnosis Autoantibodies are regarded as specific; however, better standardization of techniques and esti-
mates of the diagnostic accuracy are warranted
Underdiagnosis Sensitivity is currently low
CMT = Charcot-Marie-Tooth disease; HNLPP = hereditary neuropathy with liability to pressure palsy; MMN = multifocal motor neuropathy; POEMS = polyneuropathy, organome-
galy, endocrinopathy, monoclonal protein, skin changes.
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Interpretation of CMAP amplitude reductions as conduc-
tion blocks should be done with care in trajectories of nerves
that are adjacent to each other, as co-stimulation and
co-registration may occur. Moreover, physiological anasto-
moses, such as the Martin-Gruber anastomosis, have to be
considered. These reasons should be ruled out prior to
concluding that (apparent) CMAP reductions are due
to conduction blocks, especially in the lower arm segment of
the median or the ulnar nerve.
Both severely lengthened minimal F-wave latencies and ab-
sent F-waves may be classified as demyelinating features, but
these findings are not specific, especially in case of the fibu-
lar nerve (Puksa et al., 2003; Argyriou et al., 2006; Pastore-
Olmedo et al., 2009). However, F-wave analysis may be of
diagnostic utility when more distal NCS are found normal
in presence of clinical features suggestive of the diagnosis
(Rajabally and Varanasi, 2013).
The distal CMAP duration criterion in the guideline has
been debated as it does not take differences in filter settings
between centres into account (Isose et al., 2009), which can
greatly influence the duration (Rajabally et al., 2012;
Mitsuma et al., 2015). However, when cut-off values are
adjusted based on the filter settings used in the individual
centre, it is a useful criterion that can aid diagnosis with lim-
ited testing.
Sensory NCS are not included in the electrodiagnostic cri-
teria but can support sensory involvement and may be of
value as one of the supportive criteria in the ENFS/PNS
guidelines. Currently, a normal sural with abnormal median
(excluding median neuropathy at the wrist from carpal tun-
nel syndrome) or radial sensory nerve action potential
(SNAP) and/or a conduction velocity of 580% of lower
limit of normal (570% if SNAP amplitude 580% of lower
limit of normal) are included as supportive criteria (Van den
Bergh et al., 2010). Additional review of the literature does
not justify a more prominent position for sensory NCS in
the guidelines and suggests that the evidence for the current-
ly included supportive criteria, is limited with particularly
low sensitivity levels (Kimura et al., 1986; Kincaid et al.,
1988; Tamura et al., 2005; Rajabally and Narasimhan,
2007; Bragg and Benatar, 2008; Rajabally and
Samarasekera, 2010). Patients with clinically pure sensory
involvement often also have motor abnormalities at NCS
that can lead to the diagnosis of CIDP. However, an uncer-
tain proportion of these patients with pure sensory involve-
ment do not fulfil the electrophysiological criteria for at least
possible CIDP, as these are based on motor NCS (Van den
Bergh et al., 2010). Some studies have proposed alternative
diagnostic criteria for this specific CIDP phenotype
(Ayrignac et al., 2013).
In clinical practice the order and extensiveness of NCS
vary widely. If too few nerve segments are tested, this may
lead to underdiagnosis. The guideline advises to first test the
median and ulnar nerve at one forearm and the fibular and
tibial nerve of one lower leg (Van den Bergh et al., 2010).
However, in case of CIDP suspicion, there are arguments to
initiate the study with the median and the ulnar nerves up to
Erb’s point, including F-waves, as demyelinating features
may more often be found in the arms, including the more
proximal (above) elbow to axilla and axilla to Erb’s point
segments, than in the legs (Rajabally et al., 2005; Rajabally
and Narasimhan, 2011a; Lucke et al., 2019b). CMAP ampli-
tudes of distal leg muscles are often too low for proper inter-
pretation, while the proximal parts of the leg nerves are not
accessible for NCS. Moreover, proximal CMAP amplitude
reductions and temporal dispersion in the legs should be
interpreted more stringently, taking into account physiologic-
al phenomena, especially in the tibial nerve. One study dem-
onstrated that conduction blocks at the axilla and Erb’s
point were highly specific for CIDP and that proximal inves-
tigations improved the sensitivity of the diagnostic criteria
(Rajabally and Jacob, 2006). This study defined a block at
Erb’s point as an amplitude reduction of 450% between
wrist and Erb’s point (Rajabally and Jacob, 2006). However,
determining a block at Erb’s point may be challenging, with
a higher risk of submaximal stimulation at Erb’s point due
to the depth of the nerves, and no more proximal sites to ver-
ify CMAP amplitude reduction. Optimal stimulation at Erb’s
point is especially of importance, as CMAP amplitude reduc-
tions in normal control subjects may be substantial over lon-
ger arm nerve trajectories due to physiological temporal
dispersion (Johnsen et al., 2006).
CSF examination
Elevated protein in the CSF with normal leucocytes is found
in up to 90% of patients with typical CIDP and is thought
to be one of the hallmark features of the disease (Dyck
et al., 1975; Prineas and McLeod, 1976; McCombe et al.,
1987). In atypical CIDP variants such as the asymmetric
subtype, protein elevation might be less pronounced, or ab-
sent (Rajabally and Chavada, 2009). Elevation of the CSF
protein is not specific for CIDP and especially patients with
diabetes mellitus or hereditary demyelinating neuropathies
(CMT1) can have slightly elevated protein levels (Bouche
et al., 1983; Kobessho et al., 2008). To prevent misdiag-
nosis, it was recently suggested to increase the cut-off value
for CSF protein to 0.6 g/l in patients older than 50 (Breiner
et al., 2019). If an elevated leucocyte count (410/mm3) is
found, infections or malignancies should be considered.
However, slightly elevated leucocyte counts (410 mm3)
have been reported in up to 11% of CIDP patients (van
Doorn et al., 1991; Press et al., 2003; Lucke et al., 2018),
meaning that this does not automatically exclude the diagno-
sis. One study found that 8 of 14 (57%) patients with ele-
vated leucocytes (410 mm3) had a (sub)acute onset of
disease and that leucocytes spontaneously decreased over
time (Lucke et al., 2018).
Imaging
MRI and nerve ultrasound can be a valuable addition in the
diagnostic work-up, as proximal segments such as the prox-
imal part of the brachial plexus and the lumbosacral plexus
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can be assessed, while NCS cannot study these regions. In
both techniques, one of the main parameters is nerve hyper-
trophy. It is noteworthy that this is not an exclusive phe-
nomenon for acquired inflammatory neuropathies such as
CIDP and may be seen in other relatively prevalent diseases
such as diabetes mellitus, hereditary demyelinating neuropa-
thies and neuralgic amyotrophy (Breiner et al., 2017; Padua
et al., 2018; van Rosmalen et al., 2019).
Multiple studies were carried out to evaluate MRI in
CIDP with widely varying results: nerve hypertrophy was
found in 37–100% of cases (Tazawa et al., 2008; Sinclair
et al., 2011; Lozeron et al., 2016; Goedee et al., 2017a;
Jongbloed et al., 2017), hyperintensity ranged from
56–100% (Adachi et al., 2011; Sinclair et al., 2011;
Shibuya et al., 2015; Goedee et al., 2017a; Jongbloed
et al., 2017) and enhancement after gadolinium adminis-
tration was reported in 0–69% (Midroni et al., 1999;
Adachi et al., 2011; Goedee et al., 2017a). Most cohorts
had small sample sizes and consisted of prevalent cases
with a typical presentation, who met the electrophysio-
logical criteria for definite CIDP. Only few studies
included a clinically relevant control group, leading to less
generalizable results for the daily practice where distin-
guishing CIDP from its differential diagnoses is often diffi-
cult. A recent study has evaluated the diagnostic
performance of MRI in differentiating CIDP and multi-
focal motor neuropathy from disease controls (segmental
spinal muscular atrophy) and healthy control subjects
(Oudeman et al., 2020). In that study, intra- and inter-
observer agreement for qualitative assessment of nerve
hypertrophy and hyperintensity as scored on STIR varied
widely. This was also the case for qualitative scoring on
magnetic resonance neurography, a newer sequence
technique.
Several studies showed changes in diffusion tensor imaging
in CIDP, a technique that enables quantitative measurements
of water diffusivity within nerve tissue, but the diagnostic
contrast seems relatively small and may not be useful in clin-
ical practice (Kakuda et al., 2011; Markvardsen et al., 2016;
Kronlage et al., 2017; Oudeman et al., 2020). Given the
rapid development of MRI techniques, the aim may be to
develop other preferably quantitative measures suited to per-
ipheral nerve tissue in health and disease.
Increases in nerve cross-sectional area on nerve ultrasound
have been reported in several studies. Nerve enlargement
was found in 69–100% of CIDP patients (Matsuoka et al.,
2004; Zaidman et al., 2009; Sugimoto et al., 2013). Studies
showed that the CSA of the brachial plexus and the median
nerve were the most adequate measurements to distinguish
between CIDP and axonal neuropathy (Grimm et al., 2014;
Goedee et al., 2017b). A recent single centre study provided
cut-off values based on the upper limits for axonal neuropa-
thies and found a 100% specificity for enlargement of one
or more segments of the median nerve or the cervical trunci/
roots (Goedee et al., 2017b). However, also in this study,
only patient controls with a clear-cut diagnosis of axonal
neuropathy or amyotrophic lateral sclerosis were studied. A
more recent single centre study that included 100 patients
clinically suspected of an acquired inflammatory neuropathy
found a high sensitivity (97%) for nerve ultrasound, but the
specificity was lower than previously reported (69%)
(Herraets et al., 2020). In addition, ultrasound identified
patients that responded to treatment but did not meet the
electrodiagnostic criteria (Herraets et al., 2020).
A good inter-observer variability of the nerve ultrasound
was shown in a multicentre study, including acquired in-
flammatory neuropathies (Telleman et al., 2019). An advan-
tage of nerve ultrasound over MRI is that nerve ultrasound
is a relatively easy, quick, patient-friendly tool.
Evoked potentials
SSEP and triple stimulation technique (TST) may be of help
in diagnosing CIDP. SSEPs are used to assess the functioning
of the whole sensory pathway, including the nerve roots.
The evidence that supports the use of SSEP in diagnosing
CIDP is limited. Proximal sensory nerve involvement as
investigated with SSEP was found in 38–100% of CIDP
cases (Pineda et al., 2007; Yiannikas and Vucic, 2008;
Tsukamoto et al., 2010; Salhi et al., 2014). Sample sizes of
these studies were often small. None of the studies investi-
gated the diagnostic utility of SSEP in treatment-naı̈ve
patients or with the use of SSEP as a primary investigation.
The role of the SSEP in diagnosing CIDP is clearly limited if
the electrodiagnostic criteria are met. However, studies
showed that in up to 100% of patients with a pure sensory
presentation, who did not meet the electrophysiological crite-
ria, SSEP showed involvement of the nerve roots (Sinnreich
et al., 2004; Ayrignac et al., 2013). In clinical practice, SSEP
should be considered in patients with predominant sensory
ataxia and areflexia, if the electrodiagnostic criteria are not
fulfilled.
Another potential method to overcome the challenges of
assessing demyelination in proximal parts might be motor
evoked potentials. Several explorative studies using motor
evoked potentials in CIDP showed (very) prolonged periph-
eral conduction times and, less often, changes in central con-
duction times, but formal diagnostic accuracy studies have
not been performed (Takada and Ravnborg, 2000; Pineda
et al., 2007). TST is a specialized diagnostic tool to examine
the nerve roots proximal of Erb’s point, and includes the use
of motor evoked potentials. It may demonstrate proximal
motor conduction blocks, even if patients do not meet the
electrodiagnostic criteria (Attarian et al., 2015; Cao et al.,
2018), indicating that TST can probably increase sensitivity.
However, specificity is yet unknown and there is very limited
experience with this technique.
Nerve biopsy
Whether nerve biopsy has additional value in diagnosing
CIDP has long been a matter of debate. Usually, the nerve
selected for biopsy is the sural nerve, as it is easily accessible.
The pathological findings are segmental demyelination and
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remyelination, onion bulb formation and inflammatory infil-
trates (Krendel et al., 1989). These findings were reported in
48–71% of the biopsies in patients that met diagnostic
criteria (Barohn et al., 1989; Krendel et al., 1989;
Molenaar et al., 1998; Bouchard et al., 1999). However, sam-
ple sizes of the studies were small and few studies compared
biopsy results from CIDP patients with disease controls. One
study suggested that none of the biopsy findings were specific
for CIDP, as these findings were also found in vasculitis,
axonal and demyelinating hereditary neuropathies and mono-
clonal gammopathies (Krendel et al., 1989). Other studies
also showed that nerve biopsies failed to differentiate between
CIDP and axonal neuropathies or diabetic neuropathies
(Molenaar et al., 1998; Uncini et al., 1999; Bosboom et al.,
2001). Some studies suggested that there might be some value
in atypical CIDP cases (Vallat et al., 2003; Ayrignac et al.,
2013). The recent discovery of specific nodal and paranodal
abnormalities in the ultrastructural analysis of the nerve in
patients with antibodies against node of Ranvier cell adhesion
molecules may have diagnostic utility in specific patients
(Koike et al., 2017; Vallat et al., 2017; Uncini and Vallat,
2018). Nerve biopsy is considered invasive and will lead to
persisting sensory loss in most patients, while persisting pain,
infections and dysaesthesias have also been reported in a mi-
nority of patients (Gabriel et al., 2000; Ruth et al., 2005).
Autoantibodies
Autoantibody search has been an important topic of re-
search in CIDP in the last decades, but just recently, sub-
groups of CIDP patients with antibodies targeting the nodes
of Ranvier and paranodal regions have been described
(Querol et al., 2017a; Vural et al., 2018). The discovery of
these antibodies, associating with antibody-specific clinical
features, boosted interest in the role of antibodies as diag-
nostic and prognostic biomarkers. Up to 25% of patients
with CIDP show evidence of circulating autoantibodies tar-
geting antigens of the peripheral nerve structures, including
nodal and paranodal regions (Querol et al., 2017b; Vural
et al., 2018; Broers et al., 2019). Autoantibodies specifically
targeting the nodal and paranodal regions are found in
10% of CIDP patients. Antibodies to neurofascin 155
(NF155) are the most frequent, while antibodies to neurofas-
cin 140 (NF140) and neurofascin 186 (NF186), contactin-1
(CNTN1) and contactin-associated protein 1 (CASPR1) are
less common (Querol et al., 2017a; Vural et al., 2018;
Bunschoten et al., 2019). Most are of the IgG4 isotype. A
systematic review reported a very low sensitivity of these
autoantibodies but specificities of 100% in CIDP (Hu et al.,
2018). Specific clinical phenotypes have been described in
patients with autoantibodies to the nodes and paranodes
(Table 3). In general, antibodies to nodal and paranodal
proteins, regardless of the autoantibody, associate with a
subacute onset and more progressive CIDP phenotypes, ini-
tially often classified as Guillain-Barré syndrome, and poorer
responses to immunoglobulins than patients without these
autoantibodies (Hu et al., 2018; Vural et al., 2018). The
clinical significance of antibodies other than those targeting
nodal and paranodal proteins is unclear.
The optimal technical approach to test for nodal/parano-
dal antibodies is currently under investigation. However,
most published studies use cell-based assays (either immuno-
cytochemistry or flow-cytometry) performed with HEK293
cells transfected with the human recombinant protein target
of the antibodies, ELISAs using human recombinant proteins
as the protein substrate or immunohistochemistry on teased-
nerve fibres to detect the typical nodal or paranodal staining.
Considering that the detection of these autoantibodies usual-
ly leads to the use of therapeutic algorithms that includes
therapies (e.g. rituximab) that are not first line therapies in
CIDP, it seems reasonable to try to confirm the detected
antibodies with at least two different techniques to increase
diagnostic specificity (Martı́n-Aguilar et al., 2020).
Two independent series, in which in a total of 113 patients
were included, described six patients fulfilling the diagnostic
criteria for CIDP, in which anti-MAG antibodies were
detected in the absence of IgM paraproteinaemia. These
patients presented and progressed similar to anti-MAG-posi-
tive patients with IgM paraproteinaemia (Sakamoto et al.,
2017; Pascual-Go~ni et al., 2019) and two of them developed
detectable paraproteinaemia years after disease-onset, sug-
gesting that a subset of patients classified as distal CIDP
could indeed be patients with early anti-MAG-positive
monoclonal gammopathy of undetermined significance
related polyneuropathy (MGUSP) (Allen and Lewis, 2015).
It is important to take this into account to avoid misdiag-
nosis, especially in patients with the distal phenotype.
Testing for antibodies should be considered in treatment
unresponsive patients, especially in the presence of atypical
symptoms such as a subacute onset, severe ataxia, pain or a
tremor. In case of the distal phenotype and treatment unre-
sponsiveness, M-protein reanalysis and anti-MAG antibodies
may be considered. International, multicentric studies are
currently underway, which focus on standardization of
Table 3 Characteristics of patients with autoantibodies
in CIDP
Characteristics
Neurofascin 155 (NF155) Subacute onset, fast progression
Younger age
Distal motor involvement
Ataxia
Prominent, low-frequency tremor
(Querol et al., 2014;
Devaux et al., 2016)
Neurofascin 140 and 186
(NF140 and NF186)
Subacute onset, fast progression
Cranial nerve deficits
Ataxia(Delmont et al., 2017;
Stengel et al., 2019)
Contactin-1 (CNTN1) Subacute onset, fast progression
Axonal involvement at onset
Ataxia
(Querol et al., 2013;
Miura et al., 2015)
Contactin-associated
protein 1 (CASPR1)
Severe pain
(Doppler et al., 2016)
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measuring autoantibodies, but also on providing better esti-
mates of the diagnostic accuracy of autoantibody testing in
patients suspected of CIDP. If autoantibody testing is shown
to be widely reliable and reproducible, it can be introduced
for standard clinical practice.
Discussion
CIDP has a very heterogeneous presentation, and consists of
a spectrum of autoimmune diseases of the peripheral nerves
based on presumed breach of tolerance leading to auto-
immunity against nerve antigens. Different pathophysiologic-
al mechanisms have been identified, often sharing clinical
features, which makes diagnosis challenging.
The term CIDP was introduced in 1982 describing some
of the most common features of the disease in four different
domains, namely time of onset, pathophysiology, tissue com-
ponent involved and anatomical distribution. However, the
use of this term has evolved over time to try to incorporate
other patients with primary chronic immune-mediated neu-
ropathies susceptible to disease-modifying therapies that
share but do not necessarily include all of the original fea-
tures. More importantly, as our knowledge of the disease
deepens, it has become increasingly difficult to unite all clin-
ical presentations and pathophysiological mechanisms under
this term, some even contradicting the original terminology.
First, CIDP may have an acute onset, that initially resembles
Guillain-Barré syndrome (Vural et al., 2018). Also, some
neuropathies meet various supportive criteria, including
treatment response, but not the electrophysiological criteria
(Lucke et al., 2019a; Herraets et al., 2020). However, the
best examples are the recently discovered nodal and parano-
dal neuropathies that are caused by autoantibodies. Some
are autoantibodies to axonal nodal structures, such as
CNTN1, so that it became clear that autoimmunity can be
primarily directed to axonal antigens, and not only to mye-
lin antigens. In case of anti-CNTN1, electron microscopy
examination showed a selective loss of the septate-like junc-
tions at the paranodes and a detachment of the paranodal
myelin loops from the axon, but there was an absence of in-
flammation and classical macrophage-induced demyelination
(Kouton et al., 2020). Importantly, this disorganization of
the nodes of Ranvier disrupts the saltatory conduction,
which leads to electrophysiological findings that are trad-
itionally interpreted as demyelinating features. The electro-
physiological criteria for CIDP were originally intended to
be able to detect the physiological substrate of demyelin-
ation, as this was the only known underlying pathology.
However, in essence they are markers for functional disrup-
tion or slowing of the saltatory conduction of myelinated
axons. In the context of CIDP, conduction block can result
from paranodal abnormalities of the myelin sheath, but also
from primary dysfunction of the axon at the nodes of
Ranvier. Considering that inflammation and demyelination
as core features are not present in all CIDP patients, while
an autoimmune aetiology is presumed in all patients, the
umbrella term ‘chronic autoimmune neuropathies’ may fit
Figure 1 A conceptual framework for a diagnostic work-up in chronic autoimmune neuropathies. A conceptual framework for a
diagnostic work-up in chronic auto-immune neuropathies, assuming future emphasis on immunological tests with high specificity to show evi-
dence for autoimmunity. Combinations and number of tests required for diagnosis depend on specificity of clinical phenotypes, of immunological
tests and of supportive tests, such as nerve conduction studies, imaging, CSF examination, pathology and response to treatment. NCS currently
have the best diagnostic accuracy.
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better (Fig. 1). Further discussion will be needed on whether
to include other entities such as multifocal motor neuropathy
and anti-MAG neuropathy within this term. Recent studies
suggested that anti-MAG antibodies can be present in few
patients with CIDP without the presence of IgM paraprotei-
naemia. However, in an overwhelming majority of patients
there is also IgM paraproteinaemia, suggesting that the
underlying pathomechanism is plasma cell dyscrasia rather
than breach of tolerance. Moreover, further studies are
needed to determine the diagnostic cut-off of anti-MAG anti-
bodies in those patients without IgM paraproteins as these
can also be found in low quantities in other conditions.
Regardless of the nomenclature, if we consider the auto-
immune aetiology as the hallmark of the disease, in the fu-
ture we should also probably focus more on introducing
specific immunological tests in our diagnostic work-up. This
would be in line with the diagnostic approaches of other,
similarly heterogeneous, autoimmune diseases, in which ac-
cess to tissue is difficult, such as autoimmune encephalopa-
thies (Graus et al., 2016). Unfortunately, despite recent
progress, finding proof of autoimmunity is currently difficult
as antibodies in blood/CSF are only found in a minority of
patients, while unambiguous pathology results from nerve
biopsy supporting an autoimmune origin are uncommon.
However, other autoantibody reactivities or markers of
autoimmunity, including immunity-related genes, may be
identified in the future (Nevo et al., 2013; Staudt et al.,
2017).
Despite desirable future advances to prove autoimmunity
in more patients, the diagnosis of CIDP currently remains a
clinical one, with greater complexity and concurrently
increased uncertainty for atypical versus typical forms. The
absence of a golden standard challenges proper evaluation
of diagnostic accuracy of tests. Still, taking surrogate stand-
ards, such as fulfilment of consensus criteria and treatment
response, partially overcomes this problem. Recognizing the
technical difficulties and caveats as outlined in this review,
will hopefully reduce the number of patients with misdiag-
nosis and underdiagnosis, particularly in non-expert environ-
ments. Currently, in the majority of patients, the diagnosis is
supported by electrophysiological evidence of impaired salta-
tory conduction, so that NCS still are the most reliable and
widely available diagnostic test to support the diagnosis of
CIDP. A slightly elevated CSF protein level has a poor speci-
ficity, while normal protein levels do not exclude the diagno-
sis. If imaging is required, nerve ultrasound is probably
preferred as it is quicker, easier and has a higher diagnostic
accuracy compared to MRI, but further multicentre studies
are needed. The role of evoked potentials and nerve biopsy
is very limited in most patients and should be reserved for
selected cases. Finally, progression should be made in stand-
ardized detection of currently available autoantibodies, of
new autoantibodies and of other evidence for autoimmunity
to improve diagnostic accuracy, so that these tests may be-
come more useful in standard clinical practice. With the last
update of the guidelines almost 10 years ago and the
introduction of the nerve ultrasound and the discovery of
autoantibodies in CIDP, the update of the EAN/PNS diag-
nostic guidelines is much awaited.
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HH, et al. Auto-antibodies to contactin-associated protein 1 (Caspr)
in two patients with painful inflammatory neuropathy. Brain 2016;
139: 2617–30.
Dyck PJ, Lais AC, Ohta M, Bastron JA, Okazaki H, Groover RV.
Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc
1975; 50: 621–37.
Eftimov F, Winer JB, Vermeulen M, de Haan R, van Schaik IN.
Intravenous immunoglobulin for chronic inflammatory demyelinat-
ing polyradiculoneuropathy. Cochrane Database Syst Rev 2013;
CD001797.
Gabriel CM, Howard R, Kinsella N, Lucas S, McColl I, Saldanha G,
et al. Prospective study of the usefulness of sural nerve biopsy. J
Neurol Neurosurg Psychiatry 2000; 69: 442–6.
Goedee HS, Jongbloed BA, van Asseldonk J-TH, Hendrikse J,
Vrancken AFJE, Franssen H, et al. A comparative study of brachial
plexus sonography and magnetic resonance imaging in chronic in-
flammatory demyelinating neuropathy and multifocal motor neur-
opathy. Eur J Neurol 2017a; 24: 1307–13.
Goedee HS, van der Pol WL, van Asseldonk J-TH, Franssen H,
Notermans NC, Vrancken AJFE, et al. Diagnostic value of sonog-
raphy in treatment-naive chronic inflammatory neuropathies.
Neurology 2017b; 88: 143–51.
Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, et al. A
clinical approach to diagnosis of autoimmune encephalitis. Lancet
Neurol 2016; 15: 391–404.
Grimm A, Heiling B, Schumacher U, Witte OW, Axer H. Ultrasound
differentiation of axonal and demyelinating neuropathies. Muscle
Nerve 2014; 50: 976–83.
Herraets IJT, Goedee HS, Telleman JA, van Eijk RPA, van Asseldonk
JT, Visser LH, et al. Nerve ultrasound improves detection of treat-
ment-responsive chronic inflammatory neuropathies. Neurology
2020; 94: e1470–9.
Hu W, Xin Y, He Z, Zhao Y. Association of neurofascin IgG4 and
atypical chronic inflammatory demyelinating polyneuropathy: a sys-
tematic review and meta-analysis. Brain Behav 2018; 8: e01115.
Hughes RA, Mehndiratta MM, Rajabally YA. Corticosteroids for
chronic inflammatory demyelinating polyradiculoneuropathy.
Cochrane Database Syst Rev 2017; CD002062.
Hughes RAC, Bouche P, Cornblath DR, Evers E, Hadden RDM,
Hahn A, et al. European Federation of Neurological Societies/
Peripheral Nerve Society guideline on management of chronic in-
flammatory demyelinating polyradiculoneuropathy: report of a joint
task force of the European Federation of Neurological Societies and
the Peripheral Nerve Society. Eur J Neurol 2006; 13: 326–32.
Isose S, Kuwabara S, Kokubun N, Sato Y, Mori M, Shibuya K, et al.
Utility of the distal compound muscle action potential duration for
diagnosis of demyelinating neuropathies. J Peripher Nerv Syst 2009;
14: 151–8.
Johnsen B, Fuglsang-Frederiksen A, de Carvalho M, Labarre-Vila A,
Nix W, Schofield I. Amplitude, area and duration of the compound
muscle action potential change in different ways over the length of
the ulnar nerve. Clin Neurophysiol 2006; 117: 2085–92.
Jongbloed BA, Bos JW, Rutgers D, van der Pol WL, van den Berg LH.
Brachial plexus magnetic resonance imaging differentiates between
inflammatory neuropathies and does not predict disease course.
Brain Behav 2017; 7: e00632.
Kakuda T, Fukuda H, Tanitame K, Takasu M, Date S, Ochi K, et al.
Diffusion tensor imaging of peripheral nerve in patients with chronic
inflammatory demyelinating polyradiculoneuropathy: a feasibility
study. Neuroradiology 2011; 53: 955–60.
Kimura J, Machida M, Ishida T, Yamada T, Rodnitzky RL, Kudo Y,
et al. Relation between size of compound sensory or muscle action
potentials, and length of nerve segment. Neurology 1986; 36:
647–52.
Kincaid JC, Minnick KA, Pappas S. A model of the differing change in
motor and sensory action potentials over distance. Muscle Nerve
1988; 11: 318–23.
Kobessho H, Oishi K, Hamaguchi H, Kanda F. Elevation of cerebro-
spinal fluid protein in patients with diabetes mellitus is associated
with duration of diabetes. Eur Neurol 2008; 60: 132–6.
Koike H, Kadoya M, Kaida KI, Ikeda S, Kawagashira Y, Iijima M, et
al. Paranodal dissection in chronic inflammatory demyelinating
polyneuropathy with anti-neurofascin-155 and anti-contactin-1 anti-
bodies. J Neurol Neurosurg Psychiatry 2017; 88: 465–73.
Koski CL, Baumgarten M, Magder LS, Barohn RJ, Goldstein J, Graves
M, et al. Derivation and validation of diagnostic criteria for chronic
inflammatory demyelinating polyneuropathy. J Neurol Sci 2009;
277: 1–8.
Kouton L, Boucraut J, Devaux J, Rajabally YA, Adams D, Antoine JC,
et al. Electrophysiological features of chronic inflammatory demyeli-
nating polyradiculoneuropathy associated with IgG4 antibodies tar-
geting neurofascin 155 or contactin 1 glycoproteins. Clin
Neurophysiol 2020; 131: 921–7.
Krendel DA, Parks HP, Anthony DC, St Clair MB, Graham DG. Sural
nerve biopsy in chronic inflammatory demyelinating polyradiculo-
neuropathy. Muscle Nerve 1989; 12: 257–64.
Diagnostic challenges in CIDP BRAIN 2020: Page 9 of 11 | 9
D
ow
nloaded from
 https://academ
ic.oup.com
/brain/advance-article/doi/10.1093/brain/aw
aa265/5957444 by guest on 18 N
ovem
ber 2020
Kronlage M, Pitarokoili K, Schwarz D, Godel T, Heiland S, Yoon M-
S, et al. Diffusion tensor imaging in chronic inflammatory demyeli-
nating polyneuropathy: diagnostic accuracy and correlation with
electrophysiology. Invest Radiol 2017; 52: 701–7.
Lozeron P, Lacour M-C, Vandendries C, Théaudin M, Cauquil C,
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Cano-Abascal A, et al. Antibodies against nodo-paranodal proteins
are not present in genetic neuropathies. Neurology 2020; 95:
e427–e433.
Matsuoka N, Kohriyama T, Ochi K, Nishitani M, Sueda Y, Mimori
Y, et al. Detection of cervical nerve root hypertrophy by ultrasonog-
raphy in chronic inflammatory demyelinating polyradiculoneurop-
athy. J Neurol Sci 2004; 219: 15–21.
McCombe PA, Pollard JD, McLeod JG. Chronic inflammatory demye-
linating polyradiculoneuropathy. A clinical and electrophysiological
study of 92 cases. Brain 1987; 110: 1617–30.
Mehndiratta MM, Hughes RA, Pritchard J. Plasma exchange for
chronic inflammatory demyelinating polyradiculoneuropathy.
Cochrane Database Syst Rev 2015; CD003906.
Midroni G, de Tilly LN, Gray B, Vajsar J. MRI of the cauda equina in
CIDP: clinical correlations. J Neurol Sci 1999; 170: 36–44.
Mitsuma S, Van den Bergh P, Rajabally YA, Van Parijs V, Martin-
Lamb D, Sonoo M, et al. Effects of low frequency filtering on distal
compound muscle action potential duration for diagnosis of CIDP: a
Japanese-European multicenter prospective study. Clin
Neurophysiol 2015; 126: 1805–10.
Miura Y, Devaux JJ, Fukami Y, Manso C, Belghazi M, Wong AH,
et al. Contactin 1 IgG4 associates to chronic inflammatory demyeli-
nating polyneuropathy with sensory ataxia. Brain 2015; 138:
1484–91.
Molenaar DS, Vermeulen M, de Haan R. Diagnostic value of sural
nerve biopsy in chronic inflammatory demyelinating polyneurop-
athy. J Neurol Neurosurg Psychiatry 1998; 64: 84–9.
Nevo Y, Ben-Zeev B, Tabib A, Straussberg R, Anikster Y, Shorer Z, et
al. CD59 deficiency is associated with chronic hemolysis and child-
hood relapsing immune-mediated polyneuropathy. Blood 2013; 121:
129–35.
Oudeman JE, Strijkers G, Verhamme C. Diagnostic accuracy of MRI
and ultrasound in chronic immune-mediated neuropathies.
Neurology 2020; 94: e62–74.
Padua L, Caliandro P, Aprile I, Sabatelli M, Madia F, Tonali P.
Occurrence of nerve entrapment lesion in chronic inflammatory
demyelinating polyneuropathy. Clin Neurophysiol 2004; 115:
1140–4.
Padua L, Coraci D, Lucchetta M, Paolasso I, Pazzaglia C, Granata G,
et al. Different nerve ultrasound patterns in charcot-marie-tooth
types and hereditary neuropathy with liability to pressure palsies.
Muscle Nerve 2018; 57: E18–e23.
Pascual-Go~ni E, Martı́n-Aguilar L, Lleixà C, Martı́nez-Martı́nez L,
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